ExploreWatchlistsPricing
  1. JP-listed companies
  2. SanBio Company Limited
  3. Financials
  4. Cash from operations

SanBio Company Limited (4592)

Market cap
¥170.1B
P/E ratio
-30.2x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from operations (Million JPY)YoY (%)
Jan 31, 2026-3,761+4.38%
Jan 31, 2025-3,603-24.39%
Jan 31, 2024-4,766-35.90%
Jan 31, 2023-7,434+13.56%
Jan 31, 2022-6,547+25.52%
Jan 31, 2021-5,216-8.77%
Jan 31, 2020-5,717+44.07%
Jan 31, 2019-3,968+108.12%
Jan 31, 2018-1,907+6.16%
Jan 31, 2017-1,796+31.87%
Jan 31, 2016-1,362+523.37%
Jan 31, 2015-219

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat